FCGR3A and ovarian neoplasm: CD64/CD16A expressed in NK-92 cells and iNK cells facilitated improved recognition and conjugation to HER2+ ovarian tumor cells treated with the anti-HER monoclonal antibody (mAb), trastuzumab, and led to enhanced IFN-γ production by CD64/CD16A-expressing NK cells.